[A20-40] Neratinib (breast cancer) - Addendum to Commission A19-98
Last updated 14.05.2020
Commission awarded on 06.04.2020 by the Federal Joint Committee (G-BA).
Extended adjuvant treatment of early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer if prior adjuvant trastuzumab-based therapy was completed less than one year ago
Due to new information from the commenting procedure now hint of a non-minor added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-98||Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2020-05-14 A G-BA decision was published.